Comments (10) Eli Lillys (LLY) obesity therapy, tirzepatide, can lead to greater weight loss but with a greater loss of lean body mass compared to Novo Nordisks (NVO) rival therapy, semaglutide, according to a new study based on real-world data
Determination of glutamate-cysteine ligase (-glutamylcysteine synthetase) activity by high-performance liquid chromatography and electrochemical detection
In this trial, 17,604 patients were assigned to receive a once-weekly injection of 2.4 mg of semaglutide or placebo (mean follow-up of 39.8 months)
Telomere length shortening leads to a reduction in mtDNA copy number
A deficiency can lead to fatigue, weakness, and neurological issues like numbness or tingling
In the latter study (94), Ex-4 was found to exert neuroprotective effects in both aged T2DM/obese and healthy mice by administrating a dose of 50 mg/kg Ex-4 from 1.5 or 3 h after MCAO